Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer

Nanoliposomal irinotecan (nal‐IRI) is a liposomal formulation of irinotecan with a longer half‐life (t(1/2)), higher plasma total irinotecan (tIRI), and lower SN‐38 maximum concentration (C (max)) compared with nonliposomal irinotecan. Population pharmacokinetic (PK) analysis of nal‐IRI was performe...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Clin Pharmacol Ther
Egile Nagusiak: Adiwijaya, BS, Kim, J, Lang, I, Csõszi, T, Cubillo, A, Chen, J‐S, Wong, M, Park, JO, Kim, JS, Rau, KM, Melichar, B, Gallego, JB, Fitzgerald, J, Belanger, B, Molnar, I, Ma, WW
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2017
Gaiak:
Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5697569/
https://ncbi.nlm.nih.gov/pubmed/28445610
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.720
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak